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Bladder exstrophy-epispadias complex (BEEC), the severe end of the urorectal malformation spectrum, has a
profound impact on continence as well as sexual and renal functions. It is widely accepted that for the majority
of cases the genetic basis appears to be multifactorial.Here, we report the first study which utilizes genome-wide
association methods to analyze a cohort comprising patients presenting the most common BEEC form, classic
bladder exstrophy (CBE), to identify common variation associated with risk for isolated CBE. We employed dis-
covery and follow-up samples comprising 218 cases/865 controls and 78 trios in total, all of European descent.
Our discovery sample identified a marker nearSALL1, showing genome-wide significant association with CBE.
However, analyses performed on follow-up samples did not add further support to these findings. We were
also able to identify an association with CBE across our study samples (discovery: P 5 8.88 3 1025; follow-
up:P5 0.0025; combined: 1.09 3 1026) in a highly conserved 32 kb intergenic region containing regulatory ele-
ments betweenWNT3andWNT9B. Subsequent analyses in mice revealed expression for both genes in the geni-
tal region during stages relevant to the development of CBE in humans. Unfortunately, we were not able to
replicate the suggestive signal for WNT3 and WNT9B in a sample that was enriched for non-CBE BEEC cases
(P 5 0.51). Our suggestive findings support the hypothesis that larger samples are warranted to identify asso-
ciation of common variation with CBE.
INTRODUCTION
The Bladder exstrophy-epispadias complex (BEEC; OMIM
%600057) represents the severe end of the urorectal malforma-
tion spectrum and has a profound impact on continence as well as
sexual and renal functions. The BEEC comprises three levels of
severity ranging from epispadias (E) (Supplementary Material,
Fig. S1A and B) and classic bladder exstrophy (CBE) (Supple-
mentary Material, Fig. S1C and D), to the most severe form,
cloacal exstrophy (CE), often referred to within the OEIS
complex (omphalocele, exstrophy, imperforate anus and spinal
defects; Supplementary Material, Fig. S1E) (1,2). In approxi-
mately, one-third of all BEEC patients, there are also associated
urological malformations (e.g. ectopic kidney, renal agenesis
and hydronephrosis). Management of the BEEC is primarily
surgical, and the main aims are the achievement of secure
abdominal wall closure, urinary continence with preservation
of renal function and adequate cosmetic and functional genital
reconstruction (3). Following reconstructive surgery of the
bladder during the neonatal period, continence rates of around
80% are expected during childhood. Additional surgery might
be needed to optimize bladder storage and emptying func-
tion. Psychosocial and psychosexual outcome and adequate
health-related quality of life depend on long-term multidiscip-
linary care (4–7). Among children of European descent, the
overall birth prevalence for the entire spectrum has been esti-
mated to be 1 in 10 000 (2). The birth prevalence for the specific
subtypes, including terminated pregnancies, has also been esti-
mated and established values for E of 1 in 117 000 for males
and 1 in 484 000 for females (2), along with 1 in 37 000 for
CBE (8) and 1 in 200 000 to 1 in 400 000 for CE (9).
Although the BEEC can occur as part of a complex malforma-
tion syndrome, the majority of cases (98.5%) are classified as
isolated (10–12). Formal genetic studies have suggested the in-
volvement of genetic factors in the etiology of BEEC. For CBE,
the recurrence risk among siblings in families with non-
consanguineous and non-affected parents ranges between 0.3
and 2.3%, and the recurrence risk for the offspring of affected
patients was reported to be 1.4% (13,14). Hence, the recurrence
risk for the offspring of affected CBE patients and the risk
of having a second affected child for parents who are non-
consanguineous and non-affected exhibits an 400-fold
increase as compared with the general population. Further evi-
dence for genetic factors underlying the BEEC comes from a
classic twin study which clearly showed higher concordance
rates among monozygotic (62%) as compared with dizygotic
(11%) twin pairs (15).
Despite the overall rare occurrence of these congenital mal-
formations, a total of 30 families with multiple affected indivi-
duals have been reported. In some of these, the pattern of
BEEC incidences within single families resembles a Mendelian
mode of inheritance (15–18); however, the general consensus in
the field is that, in the majority of patients, the genetic basis
appears to be multifactorial (11). To further support formal evi-
dence for a genetic contribution to BEEC, recent studies have
identified various molecular genetic factors including chromo-
somal aberrations such as trisomy 21 and micro-duplications
on chromosome 22q11.21, as well as the association of poly-
morphisms within the DNp63 promoter with an increased
incidence of BEEC phenotypes (19–22). However, these asso-
ciated chromosomal risk factors account for only a small
portion of the BEEC, whereas most patients represent idiopathic
cases.
To the best of our knowledge, we report here the first study
using genome-wide association methods to analyze a BEEC
cohort sample, comprising of patients presenting the most
common form, CBE. Our aim was to identify genetic susceptibil-
ity loci for isolated CBE presentation. We therefore conducted
a genome-wide association study (GWAS), and subsequently
followed up the most promising genomic regions in indepen-
dent replication samples, with the goal of identifying common
single-nucleotide polymorphisms (SNPs) in the genome that
are associated with risk for isolated CBE in patients of European
descent.













For both GWASs, we followed the same stringent quality control
(QC) protocol that has been successfully applied to other data-
sets (23,24). Details on the analytical pipeline can be found in
Supplementary Material, Figure S2. The post-QC datasets (com-
prising 43 cases and 259 controls for GWAS1 and 55 cases and
267 controls for GWAS2, respectively) were subjected to imput-
ation based on 1000 Genomes Project and HapMap 3 reference
panels (25,26). After applying postimputation QC, single
marker analyses were conducted for 4 510 680 markers each
using a logistic regression (additive model) as implemented
into SNPTEST (27). The subsequent meta-analysis of both data-
sets was performed using a fixed-effects model as implemented
into YAMAS (28). The most significant results were obtained for
two markers in (i) an intergenic region flanked by CYLD and
SALL1 for rs4785484 on chromosome 16q12.1, P ¼ 4.55 ×
1028 and (ii) in an intergenic region flanked by EEF1E1 and
SLC35B3 for rs73374907 on chromosome 6p24.3, P ¼ 6.13 ×
1028 (more information in the Supplementary Material,
Table S1; Figs 1 and 2). Follow-up on the most promising
genomic regions based on the results of the meta-analysis was
performed for a total of 75 SNPs that were successfully geno-
typed and (meta) analyzed after pruning for linkage disequilib-
rium in the initially obtained SNP list. The post-QC dataset for
our first follow-up sample comprised 27 index cases with their
parents and 120 cases/339 controls (Supplementary Material,
Table S1 and Fig. S2; for more details on the follow-up
samples, see the Materials and Methods). Based on the results
from our first follow-up sample, a second independent sample
(Follow-up 2, 51 index cases and their parents; Supplementary
Material, Table S1 and Fig. S2) was analyzed for four markers
that showed evidence of association. Evidence for replication
(nominal significant association with same directionality based
on effect allele across GWAS, Follow-up 1 and Follow-up 2)
was found for two SNPs (Table 1) located in an intergenic
region on chromosome 17 flanked by WNT3 and WNT9B
(rs9890413, PUSA ¼ 0.0095, PEU + USA¼ 0.0025) and introni-
cally to MECOM (rs56273700, PUSA ¼ 0.0423, PEU + USA¼
0.0045). The result for rs9890413 remained significant after cor-
recting for the number of tests in the second follow-up sample.
Subsequent meta-analysis of all samples tested in the discovery
and follow-up steps showed P-values of 1.09 × 1026
(rs9890413) and 1.24 × 1026 (rs56273700), respectively. It is
of note that for rs9890413 all samples (i.e. both GWAS
samples and all four follow-up samples) shared the effect
allele and the direction of the effect. Unfortunately, we were
not able to replicate our findings for the WNT3-WNT9B locus
in a final sample of 78 cases and 336 controls that was enriched
for non-CBE BEEC cases (P ¼ 0.51; more information in the
Supplementary Material). However, it is of note that the MAF
in the control cohort was higher than expected from observations
in the GWAS samples (0.36 versus 0.29 and 0.30, respectively),
and that a test for deviation from Hardy–Weinberg equilibrium
(HWE) in controls did show a trend towards significance
(P ¼ 0.067). Expression of Wnt3 and Wnt9b was detected in
the genital region of mouse embryos at all stages examined
(Fig. 3). While Wnt3 was found to be widely expressed within
the epithelia, including that of the cloacal membrane and
genital tubercle, Wnt9b was found to be strongly expressed in
the cloacal membrane between E9.5 and E10.5, and the epithelia
of the genital tubercle at later stages.
DISCUSSION
Presumably our constrained sample size did not allow us to find
association of genetic variation with CBE (or BEEC) beyond
reasonable doubt. Our results are therefore mainly to be regarded
as suggestive evidence for association and larger studies are
needed to confirm our findings. In the following, we would
like to discuss these findings in light of the statistical power for
GWAS of rare disorders such as BEEC (birth prevalence is
0.0001).
As outlined above, we found suggestive evidence for associ-
ation with CBE across our study samples (rs9890413; dis-
covery: P ¼ 8.88 × 1025; follow-up: P ¼ 0.0025) in a highly
conserved 32 kb intergenic region containing regulatory ele-
ments between WNT3 and WNT9B. However, we were not
able to replicate this finding in an independent sample that was
enriched for non-CBE BEEC cases. It is reasonable to assume
that (at least in part) the inability to find stronger evidence for as-
sociation in the intergenic region between WNT3 and WNT9b is
based on a lack in statistical power: the risk allele frequency in
our discovery samples was 30% in controls and the effect
size was estimated with an OR of 2. Under the assumption of
an additive model and genome-wide significance (5× 1028)
power of 80% to see association at this significance level
would require a sample of 357 cases (and equal number of con-
trols). While our combined study samples (comprising 218
Figure 1. Manhattan plot for meta-analysis. Results based on fixed effect meta-analysis of GWAS1 and GWAS2 signals. Dashed red line shows threshold for
genome-wide significance (P , 5 × 1028) and dashed gray line shows cut off for the selection of SNPs for follow-up genotyping (P, 1 × 1024).












Figure 2. Regional association plots for regions on chromosome 6 (EEF1E1/SLC35B3) and chromosome 16 (CYLD/SALL1). The P-values from all imputed
SNPs in the regions that passed post-imputation QC procedures are plotted against positions from the February 2009 human reference sequence, annotated by Ref
Seq genes. The most associated marker (chromosome 6: rs73374907, Pmeta ¼ 6.13 × 1028; chromosome 16: rs4785484, Pmeta ¼ 2.65 × 1028) from the
meta-analysis is indicated by a purple dot which is centered in a genomic window of 1 Mb. The strength of LD (in r2) between the top SNP and its adjacent
markers is demonstrated by the red (high) to dark blue (low) color bar (top right corner). The recombination rate (second y-axis) is plotted in light blue, according
to 1000 genomes project data. Plots were generated using Locuszoom (http://csg.sph.umich.edu/locuszoom/) (53).












cases/865 controls and 78 trios in total) comes reasonably close
to this number it has to be taken into consideration that the esti-
mated effect size is presumably inaccurate and the true effect
size is likely to be smaller (‘winner’s curse’). The lower bound-
ary of the 95% confidence interval (CI) for rs9890413 is 1.57
(which is still higher than the OR of the European replication
sample) and results in a requirement of 866 cases and an equal
number of controls to obtain genome-wide significance. Consid-
ering a recessive mode of inheritance even further increases
sample size requirements (1702 cases). On top of the above out-
lined limitations our final replication sample, comprising a
patient sample with a broader defined BEEC phenotype (includ-
ing patients with CE and E), did show evidence for deviation
from the expected allele frequencies in the controls (36 versus
31% in the independent German controls from discovery and
replication; test for deviation from HWE: P ¼ 0.067).
Similar observations with regards to the power considerations
can be made for our initial genome-wide significant hit at the
SALL1 locus. Under the assumption of valid effect size estimation
(OR ¼ 2.89), a power of 80% for observing this locus with
genome-wide significance (additive model, minor allele fre-
quency 20%) is reached with 100 cases (which is the size of
our discovery sample). However, at the lower boundary of the
95% CI (OR ¼ 2.20), an estimate that is still likely to be higher
than the true effect size, a sample size of 200 cases (additive
model) and 410 cases (recessive model) are required. For our
replication study, we attempted replication for 75 SNPs, i.e. a
P, 6.7 × 1024 was required for experiment-wide significance.
Hence, a sample of 150 cases (equal number of controls) would
have been sufficient under the assumption of an additive model
and requiring 80% power to see this experiment-wide significant
at SALL1 (369 cases for a recessive model). In sum, our datasets
could have provided enough power to detect association of
SALL1with CBE at the level of genome- or experiment-wide sig-
nificant.However, it remains tobe seen whetheroverestimation of
the effect size did hinder a reasonable assessment of power and
therefore could have hindered a valid interpretation of the results.
The effect size for common variation associated with CBE/
BEEC seems to be not higher than those observed with other
(more common) congenital disorders in human (e.g. orofacial
clefts). Association of markers at 8q24.21 with non-syndromic
cleft lip with or without cleft palate was found with an effect
size similar to the one observed with our SALL1 association
(OR ¼ 2.57, frequency of effect allele 20% in controls, 462
cases and 954 controls (29)). Accounting for winners curse
(and taking into account effect size estimates of replication
studies for 8q24.21), it is therefore reasonable to assume that
future successful GWAS in CBE/BEEC will (at least) require
a (combined) sample size of 400 cases and equal number of
controls (additive model, OR ¼ 2, risk allele frequency 20%,
power ¼ 80%). Including more controls (e.g. three times the
number of cases) potentially reduces the required number of
cases (250).
Although we consider our findings as suggestive evidence for
association, we would like to briefly put them into context with
earlier studies. We hope that insights from this discussion
might help to guide future studies. A homozygous nonsense mu-
tation in WNT3 has been associated with tetra-amelia and uror-
ectal malformations, which include persistent cloaca (30), and
loss of Wnt9b causes urogenital defects (31). Our most asso-
ciated SNP in this region (rs9890413) resides 4 kb next to
the WNT3 promoter (http://promoter.cdb.riken.jp/), a region
highly conserved among amniotes. Moreover, this transcription-
al regulatory region is CpG enriched (ObsCpG/ExpCpG:0.718)
and likely to be regulated by methylation status. Nakamura et al.
identified several potential transcription factor-binding motifs to
exist within the WNT3 promoter region (32), several of which
were previously found to be differentially expressed in human
newborn bladder exstrophy tissue and known to be important
for promotion of the embryonic urorectal septation process
(33,34). Furthermore, this region has been shown to contain
regulatory elements which regulate Wnt signaling via p63
(35). Thus, it is tempting to speculate that there are also regula-
tory domains within this intergenic region able to modulate Wnt
Table 1. Association results for rs9890413 (WNT3/WNT9b) and rs56273700 (MECOM) at all stages of the analysis: discovery, Follow-up 1 and Follow-up 2
SNP Sample N Test, P OR EA MAF
Cases Controls Cases Controls
rs9890413 Meta GWAS 98 526 Z-score, 8.88 × 1025
GWAS1 43 259 LOGISTIC, 0.0239 1.86 G 0.40 0.29
GWAS2 55 267 LOGISTIC, 0.0013 2.11 G 0.45 0.30
Follow-up 1 147 339 Z-score, 0.0390
Germany 94 278 LOGISTIC, 0.0995 1.32 G 0.39 0.32
Sweden 26 61 LOGISTIC, 0.4915 1.24 G 0.40 0.34
Spain–Italy 27 N/A TDT, 0.2752 1.63 G N/A N/A
Follow-up 2 51 N/A TDT, 0.0095 2.31 G N/A N/A
rs56273700 Meta GWAS 98 526 Z-score, 5.15 × 1025
GWAS1 43 259 LOGISTIC, 0.0074 0.48 G 0.15 0.28
GWAS2 55 267 LOGISTIC, 0.0013 0.49 G 0.15 0.29
Follow-up 1 147 339 Z-score, 0.0317
Germany 94 278 LOGISTIC, 0.0171 0.62 G 0.22 0.31
Sweden 26 61 LOGISTIC, 0.2897 0.66 G 0.23 0.31
Spain–Italy 27 N/A TDT, 0.4913 1.38 G N/A N/A
Follow-up 2 51 N/A TDT, 0.0423 0.52 G N/A N/A
N, number of cases and controls in study sample (for trio samples, the number of index patients is given in the case column); test,P, test statistic (LOGISTIC, logistic
regression; TDT, transmission disequilibrium test) used and P-value for association; EA, effect allele; OR, odds ratio (based on effect allele); MAF, minor allele
frequency (same as effect allele for both SNPs, no MAF given for trio samples).












signaling via a conserved WNT3-WNT9B-p63 regulatory
module in the context of urorectal and urogenital development.
Indeed, expression profiling of human urinary bladder exstrophy
tissue showed dysregulation of both the WNT and p63 pathways
(34,36,37). Furthermore, the only known BEEC-associated
animal knockout model to date is the DNp632/2 mouse
described by Cheng et al. (38), who were recently able to show
association of a 12 bp deletion within the TP63 promoter in
BEEC patients of Canadian, U.S. American, Spanish origins
and a 4 bp insertion in BEEC patients of Indian, Bangladeshi
and Chinese origins (19).
We also found suggestive evidence for association of
CBE with genetic variation at the MECOM gene locus. Data
from the GenitoUrinary Development Molecular Anatomy
Project (http://www.gudmap.org) (39,40) and the GenePaint.org
project (41) suggest thatMecom is strongly expressed at E14.5 in
the metanephros, the ureter, the urinary bladder and the urethra
(39,40), and at E15.5 in the female reproductive system, the
renal interstitium, the ureteric trunk and female urethra (41).
Although E14.5–15.5 represents a developmental timeframe
later than the critical period for the urorectal septation process,
a modifier role for Mecom in the manifestation of the BEEC
Figure 3.Analysis of Wnt3 and Wnt9b expression in mid-gestational mouse embryos by in situ hybridization. (A) Expression ofWnt3was widely detected from E9.5
to E15.5, with stronger expression observed in the skin epithelia, limb buds and neural tissues.Wnt3 is also present in the genital tubercle at these stages. Expression at
E14.5 and E15.5 is not shown. gt, genital tubercle; tl, tail. (B) Expression was detectable between E9.5 and E13.5 in the epithelia of the branchial arches, frontonasal
process, limb buds and genital tubercle (including the cloacal membrane between E9.5 and E10.5). Strong expression was also found in the nephric ducts. The ex-
pression pattern of E13.5 (not shown) was identical to that at E12.5. ba, branchial arch; cm, cloacal membrane; flb, forelimb bud; fnp, frontonasal process; gt,
genital tubercle; hlb, hindlimb bud; nd, nephric duct; nt, neural tube; tl, tail.












cannot be excluded, as a recent study revealed zebrafish mecom
expression in the cloacal chamber, a space proximal to the
urogenital pore where the pronephric duct, intestine and the
oviduct or sperm duct empties (42).
The initial genome-wide significant marker rs4785484
(P ¼ 4.55 × 1028) resides close to SALL1. Patients with SALL1
mutations (Townes–Brocks syndrome, OMIM #107480) fre-
quently present with urogenital anomalies (43) and Sall1 mutant
mice exhibit neural tube defects, which can be affiliated with
the OEIS complex (44). A recent study proposed heterochromatin
localization of SALL1 as a new mechanism for the activation
of Wnt signaling (45) which was also shown to be affected
by SALL1-dependent signals in the context of ureter tip fate to
initiate kidney development (46). Future studies are warranted
to shed light on the potential interplay of SALL1 and the con-
served WNT3-WNT9B-p63 regulatory module in the etiology
of BEEC.
MATERIALS AND METHODS
Ethics statement and subjects
Written informed consent was obtained from all subjects or their
proxies, in case of minors. Demographic information was col-
lected from both patients and controls through a structured ques-
tionnaire. This study was approved by each participating
center’s Institutional Ethics Committee and was conducted
according to Declaration of Helsinki principles. Experienced
physicians trained in the diagnosis of the BEEC personally
recruited all BEEC patients included in this study. More
details about the recruitment process (for discovery and follow-
up samples) can be found elsewhere (20,47) and in the Supple-
mentary Materials, Methods.
Genetic analyses (GWAS and follow-up)
For the purposes of phenotypic homogeneity, the GWAS sample
consisted only of isolated, non-syndromic CBE, the most
common form based on the definition described in detail else-
where (2). Patients with additional malformations or congenital
anomalies, not associated with the CBE or the BEEC, respect-
ively, were excluded from the analysis. DNA was extracted from
blood or saliva samples and genotyping of 107 isolated CBE
patients of Central European ancestry was performed in two
batches (51 and 56, respectively). Due to discontinuation of
the genotyping array utilized for the first batch, different arrays
were used for Batches 1 and 2. For case–control comparison,
we also obtained genotypes of 538 (270 and 268, respectively)
ethnically matched population-based controls that have been
described elsewhere (48). All QC and subsequent procedures
were applied to both batches separately (due to insufficient
overlap in the SNP content of the utilized genotyping arrays).
For both GWASs, we followed the same stringent QC protocol
that has been successfully applied to other datasets (23,24). A
detailed description of the protocol can be found in the Supple-
mentary Materials, Methods. The post-QC datasets (comprising
43 cases and 259 controls for GWAS1 and 55 cases and 267 con-
trols for GWAS2, respectively) were subjected to imputation
based on 1000 Genomes Project and HapMap 3 reference
panels (25,26). After applying postimputation QC, single
marker analyses were conducted for 4 510 680 markers each
using a logistic regression (additive model) as implemented
into SNPTEST (27). The subsequent meta-analysis of both data-
sets was performed using a fixed-effects model as implemented
into YAMAS (28). A detailed overview on the analytical pipe-
line is provided in Supplementary Material, Figure S2. Results
from our meta-analysis (for all 4 510 680 markers) are publicly
available and can be downloaded from http://www.sharing.
biostats.info after registration with the website. Follow-up on
the most promising genomic regions was performed in a first in-
dependent sample (Follow-up 1) comprising three samples of
European ancestry from Germany (94 cases and 278 controls
post-QC), Sweden (26 cases and 61 controls post-QC), Spain
and Italy (a total of 27 trios post-QC). All analyses for the down-
stream steps were performed using PLINK (49). In order to
be selected for downstream analyses, SNPs were required to
show P, 0.0001 in the meta-analysis of the two GWAS
samples and P , 0.05 in the individual GWASs (with same
effect allele and direction of effect; see Supplementary Material,
Table S1). A total of 75 SNPs were successfully genotyped and
(meta) analyzed after pruning for linkage disequilibrium in the
initially obtained SNP list. Based on the results from our first
follow-up sample, a second independent sample (Follow-up 2)
was analyzed for four markers that showed evidence for associ-
ation (see Supplementary Material, Table S2 for results of all 75
markers). The second follow-up sample comprised of 49 trios of
European ancestry from North America with an isolated non-
syndromic CBE patient as index (post-QC number). Finally,
we attempted to replicate the most associated marker in the dis-
covery and follow-up samples in a final sample of European an-
cestry. Due to a limited number of samples available for genetic
studies on CBE, and in order to study the potential impact of
rs9890413 on a broader defined phenotype of BEEC (including
also patients with CE and E), we decided to study a sample com-
prising 78 samples (32 with CBE, 19 with CE and 27 with E;
along with 336 controls from a cohort of ethnically matched
blood donors).
Mouse expression data
Mouse embryos were fixed overnight in 4% paraformaldehyde
(PFA)/PBS and processed for in situ hybridization as described
elsewhere (50). For hybridization on sections (E12.5–E15.5),
embryos were processed into paraffin wax and sections (5 mm)
were made using a microtome. Antisense RNA probes were
transcribed from PCR products generated either from our
in-house MAMEP collection (Wnt9b) (51) or as previously
described for Wnt3 (52), which was kindly made available by
Andy McMahon. Riboprobes were synthesized using the appro-
priate RNA polymerases and a nucleotide mix containing
digoxigenin-11-UTP (Roche Diagnostics, Mannheim, Germany)
and were purified using G-50 sephadex columns (GE-Healthcare,
Solingen, Germany). Following probe hybridization and washes,
an anti-DIG antibody conjugated to alkaline phosphatase (AP)
(Roche Diagnostics, Mannheim, Germany) was incubated with
embryos overnight at 48C, and detection of AP activity was
carried out using BM Purple (Roche Diagnostics, Mannheim,
Germany). For each probe, embryos were processed concurrently
and staining reaction times were maintained between embryos in
order to limit variations in signal intensity. For whole mounts, at












least three embryos were examined for each gene and stage. For
slides, three sections from at least two different embryos were ana-
lyzed for each stage shown and figures depict representative stain-
ing. Images were captured using AxioVision software (Zeiss, Jena,
Germany) with a Zeiss AxioCam and SteREO Discovery.V12
microscope.
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